Presentation by Rachel Shi, Genentech: Innovating Mass Spectrometry Approaches for Characterizing Emerging Modality Therapeutics
Presentation by Ben Niu, BMS: High-Throughput and Automation in Novel Modalities (bsAbs, ADCs) Characterizations and Beyond
Presentation by Serena Wu, Regeneron: Development of LCMS MAM for Protein and Oligonucleotide Therapies
Presentation by Aaron Bailey, AbCellera: Leveraging the Versatility of Size Exclusion Coupled to Mass Spectrometry (SEC-MS) to Accelerate Antibody Drug…
Presentation by Chris Chumsae, BMS: Mass Spec Allows Us to ‘See’ Molecules and Solve Mysteries
Presentation by Anita Liu, Merck: Use of MAM for In-Process Monitoring and Quality Control of Complex Biologics